ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1632

Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

Sherri Longobardi1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Constantin Georgescu1, Christina Lawrence1, Astrid Rasmussen1, Lida Radfar2, R. Hal Scofield2, Robert C. Axtell1, Gabriel Pardo1, Jonathan Wren1, Kristi A Koelsch1, Joel Guthridge1, Judith James1, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), B-Cell Targets, proteomics, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

Session Type: Abstract Session

Session Time: 9:00AM-10:00AM

Background/Purpose: Classification of Sjögren’s disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD cases lack Ro autoantibodies. Here we used human proteome arrays to identify autoantibodies in Ro antibody negative SjD.

Methods: A discovery dataset was generated by testing SjD salivary gland plasmablast-derived monoclonal antibody pools (n=83 mAbs in 14 pools), stimulated parotid saliva (n=11 SjD), and plasma (n=30 SjD, n=15 HC) on human proteome arrays containing 15,500-19,500 proteins. A validation dataset was generated by testing plasma and stimulated parotid saliva from additional SjD cases (n=46 anti-Ro+, n=50 anti-Ro–), HC (n=42), and other disease (OD) controls (n=54) on custom arrays containing 150 proteins. For each protein, the mean + 3SD of the HC value was used as the threshold for positivity. Differences from HC were determined by Fisher’s Exact test at p< 0.1 and by random forest machine learning and receiver operative curve (ROC) analysis, using 2/3 of the validation dataset to train and 1/3 of the validation dataset to test the ability of the model to assign subject status. Select proteins were additionally validated by capillary Western blot. Relationships among antigens were explored using STRING interactome analysis.

Results: Ro+ SjD parotid saliva contained antibodies binding to Ro60, Ro52, La/SS-B, and muscarinic receptor 5 (MR5). SjD plasma contained 13 novel autoantibody specificities, 11 of which were detected in both discovery and validation datasets. Binding to ³1 of the novel antigens identified 41% of Ro+ SjD cases and 54% of Ro– SjD cases. ROC analysis using binary (positive/negative) data and excluding binding to the canonical Ro60, Ro52 and La antigens showed ROC area under the curve (AUC) of 0.79 (95% CI 0.64-0.93) for distinguishing Ro– SjD cases from HC. Non-canonical autoantibodies could also distinguish Ro+ SjD cases (AUC 0.63, 95% CI 0.65-0.67) but not OD cases (AUC 0.37, 95% CI 0.31-0.31) from HC. STRING interactome analysis filtered on pathways including ³2 novel antigens identified leukemia cell, ubiquitin mediated proteolysis, antiviral defense, and cytosolic DNA sensing as possible pathways targeted by the autoimmune response in Ro– SjD.

Conclusion: We have identified novel antigenic targets of the autoantibody response in SjD that may be useful for identifying a substantial proportion of Ro seronegative SjD cases without a lip biopsy.


Disclosures: S. Longobardi, None; C. Lopez-Davis, None; B. Khatri, None; C. Georgescu, None; C. Lawrence, None; A. Rasmussen, None; L. Radfar, None; R. Scofield, None; R. Axtell, Progentec, EMD-Serono; G. Pardo, Bristol-Myers Squibb(BMS), Celgene, AbbVie/Abbott, Genentech, Janssen, Novartis, Roche; J. Wren, None; K. Koelsch, None; J. Guthridge, None; J. James, Bristol-Myers Squibb(BMS), AstraZeneca, Novartis, Progentec Biosciences; C. Lessard, Janssen; A. Farris, Janssen.

To cite this abstract in AMA style:

Longobardi S, Lopez-Davis C, Khatri B, Georgescu C, Lawrence C, Rasmussen A, Radfar L, Scofield R, Axtell R, Pardo G, Wren J, Koelsch K, Guthridge J, James J, Lessard C, Farris A. Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/novel-autoantibodies-identify-sjogrens-disease-in-patients-lacking-serum-igg-specific-for-ro-ss-a-and-la-ss-b/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-autoantibodies-identify-sjogrens-disease-in-patients-lacking-serum-igg-specific-for-ro-ss-a-and-la-ss-b/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology